Integral Diagnostics Ltd
ASX:IDX
Integral Diagnostics Ltd
ASX:IDX
Price:
2.44 AUD
-2.4%
Market Closed
Updated:
May 10, 2024
P/B
Price to Book Value
Price to Book Value
1.9
Current
2
Median
2.3
Industry
Lower
than median
Lower
than industry value
Price to Book Value (P/B) ratio is a valuation multiple that measures the market's valuation of a company relative to its book value. The P/B ratio is only considered useful in practice when applied to capital-intensive businesses.
P/B
=1.9
Market Cap
/
569.6m
Book Value of Equity
300.4m
All Countries
| Market Cap | P/B | ||||
|---|---|---|---|---|---|
| AU |
|
Integral Diagnostics Ltd
ASX:IDX
|
569.6m AUD | 1.9 | |
| US |
|
Cigna Corp
NYSE:CI
|
99.7B USD | 2.4 | |
| US |
C
|
Cigna Group
XMUN:CGN
|
91.3B EUR | 2.4 | |
| US |
|
CVS Health Corp
NYSE:CVS
|
69.7B USD | 0.9 | |
| US |
|
Laboratory Corporation of America Holdings
NYSE:LH
|
17.4B USD | 2.2 | |
| DE |
F
|
Fresenius SE & Co KGaA
XETRA:FRE
|
15.8B EUR | 0.8 | |
| US |
|
Quest Diagnostics Inc
NYSE:DGX
|
15.3B USD | 2.4 | |
| DE |
F
|
Fresenius Medical Care AG & Co KGaA
XETRA:FME
|
11.4B EUR | 0.8 | |
| DE |
|
Fresenius Medical Care AG
XMUN:FME
|
11.3B EUR | 0.8 | |
| US |
|
DaVita Inc
NYSE:DVA
|
12.1B USD | 13.1 | |
| US |
|
Oak Street Health Inc
NYSE:OSH
|
9.5B USD | -34.9 |
P/B Forward Multiples
Forward P/B multiple is a version of the P/B ratio that uses forecasted equity for the P/B calculation. 1-Year, 2-Years, and 3-Years forwards use equity forecasts for 1, 2, and 3 years ahead, respectively.
1-Year Forward
P/B
N/A
2-Years Forward
P/B
N/A
3-Years Forward
P/B
N/A
You don't have any saved screeners yet
